Compare AXGN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | AGIO |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2013 | 2013 |
| Metric | AXGN | AGIO |
|---|---|---|
| Price | $40.84 | $28.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $42.33 | $38.88 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $225,208,000.00 | $43,011,000.00 |
| Revenue This Year | $20.57 | $76.75 |
| Revenue Next Year | $16.68 | $170.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.21 | N/A |
| 52 Week Low | $9.22 | $22.24 |
| 52 Week High | $45.83 | $46.00 |
| Indicator | AXGN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 47.19 |
| Support Level | $29.48 | $26.61 |
| Resistance Level | $45.14 | $29.39 |
| Average True Range (ATR) | 1.79 | 1.09 |
| MACD | -0.44 | 0.23 |
| Stochastic Oscillator | 23.52 | 76.38 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.